These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15246846

  • 21. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S, Lanza M, Makovec F, Artusi R, Caselli G, Michotte Y.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):297-305. PubMed ID: 18342306
    [Abstract] [Full Text] [Related]

  • 22. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 28; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, Picconi B, Gardoni F, Usiello A.
    Exp Neurol; 2011 Dec 01; 232(2):240-50. PubMed ID: 21946266
    [Abstract] [Full Text] [Related]

  • 30. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul 01; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 01; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 33. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    Mov Disord; 2003 Nov 01; 18(11):1301-5. PubMed ID: 14639671
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov 01; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 36. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G, Morissette M, Parent M, Di Paolo T.
    Eur J Neurosci; 2011 May 01; 33(10):1823-31. PubMed ID: 21501255
    [Abstract] [Full Text] [Related]

  • 37. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.
    Parkinsonism Relat Disord; 2013 Feb 01; 19(2):260-4. PubMed ID: 22901956
    [Abstract] [Full Text] [Related]

  • 38. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
    Kong M, Ba M, Liu C, Zhang Y, Zhang H, Qiu H.
    Behav Brain Res; 2015 Apr 01; 282():46-53. PubMed ID: 25576965
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP, Millan MJ, Brotchie JM.
    Exp Neurol; 2006 Nov 01; 202(1):85-92. PubMed ID: 16814282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.